This study is testing a special type of cell therapy called C7R-GD2.CART cells for patients aged 12 months to 25 years with certain types of GD2-expressing brain tumors, including Diffuse Intrinsic Pontine Glioma and High Grade Glioma. GD2 is a protein found on some cancer cells. The C7R-GD2.CART cells are your own immune T cells that have been specially modified in the lab to recognize and fight these cancer cells. You would receive these cells through an IV (into a vein) and ICV (into the fluid-filled space in the brain) infusion. The main goal of this study is to see how safe this treatment is and to identify any dose-limiting toxicities (side effects that are severe enough to stop treatment). The study aims to enroll 56 participants.

Study design

This is an interventional study with two treatment groups (cohorts) for different types of GD2-expressing brain tumors. It is not specified if it is randomized or blinded.

What's involved

You would have blood drawn to create the C7R-GD2.CART cells and undergo lymphodepletion (a treatment to reduce certain immune cells) before receiving the infusions. An Ommaya catheter (a special tube) would be placed in your brain for the ICV infusions.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, dose limiting toxicity, is measured at 4 weeks after the T cell infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.